Summary
Stryker Corporation's third quarter and nine-month results for 2009 indicate a resilient performance in a challenging economic environment. While net sales remained relatively flat for the quarter compared to the prior year, there was a 2% decrease year-to-date. However, the company demonstrated improved operational efficiency and cost management, with adjusted net earnings showing a slight increase in the third quarter and a modest decrease year-to-date. The Orthopaedic Implants segment continued to be a strong performer, showing consistent growth, particularly in hip, knee, and spine implant systems. Conversely, the MedSurg Equipment segment experienced a decline, impacted by weaker demand for certain products and the discontinuation of specific product lines. The company is actively managing its expenses, including a significant restructuring charge of $67.0 million recorded in the third quarter to streamline operations and reallocate resources. Despite this charge, operating income remained substantial. Stryker also highlighted its strong cash flow generation from operations and a healthy liquidity position, with ample borrowing capacity available. Management provided an outlook for full-year 2009 adjusted diluted EPS in the range of $2.90 to $3.00, indicating confidence in continued profitability.
Financial Highlights
49 data points| Revenue | $1.65B |
| Cost of Revenue | $538.70M |
| Gross Profit | $1.11B |
| R&D Expenses | $83.70M |
| SG&A Expenses | $643.90M |
| Operating Expenses | $803.20M |
| Operating Income | $311.40M |
| Net Income | $229.00M |
| EPS (Basic) | $0.58 |
| EPS (Diluted) | $0.57 |
| Shares Outstanding (Basic) | 397.60M |
| Shares Outstanding (Diluted) | 399.60M |
Key Highlights
- 1Net sales for the nine months ended September 30, 2009, decreased by 2% to $4.89 billion, while the third quarter saw a marginal increase of less than 1% to $1.65 billion, indicating a stabilization in sales trends.
- 2Restructuring charges of $67.0 million were recorded in Q3 2009, primarily related to efficiency initiatives, product line discontinuations, and workforce reductions, impacting reported net earnings but aimed at future operational improvements.
- 3The Orthopaedic Implants segment showed robust performance, with constant currency sales increasing by 6% for the nine months and 7% for the third quarter, driven by strong demand across multiple product categories.
- 4The MedSurg Equipment segment experienced a decline in sales, down 5% year-to-date and 7% in Q3 on a constant currency basis, largely due to reduced demand for patient handling and emergency medical equipment.
- 5Operating income for the nine months decreased by 6% to $1.08 billion, and by 14% for the third quarter to $0.31 billion, partly due to restructuring charges and a slight increase in cost of sales percentage.
- 6Net earnings for the nine months declined by 8% to $801.4 million ($2.01/share diluted), and by 16% for the third quarter to $229.0 million ($0.57/share diluted), impacted by restructuring charges.
- 7Cash flow from operations was strong, increasing to $920.6 million for the nine months and $465.8 million for the third quarter, demonstrating effective working capital management and operational cash generation.